2 Speculative Small-Cap Biotech Stocks That Could Double
These biotechs have no approved products yet, but they do have collaborations and clinical results that suggest their shares could be big winners down the road.
Johnson & Johnson's CEO Just Tipped His Cap in a Big Way Regarding M&A
While presenting at the J.P. Morgan Healthcare Conference, CEO Alex Gorsky laid out critical details to J&J's acquisition strategy.
Geron Corporation Exploded 49% Higher in 2015 -- Here's Why
The promise of Geron's lead experimental drug sent its shares notably higher last year, but can the good times continue in 2016?